Blog
RSS FeedPosted by Michael Wonder on 06 Mar 2023
Will reimbursement criteria of SMA treatment Spinraza change?
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen ...
Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...
Posted by Michael Wonder on 26 Jan 2023
New atopic dermatitis drugs for young patients to get expanded coverage
26 January 2023 - As the Government moves toward expanding insurance coverage for atopic dermatitis from adult to children and ...
Posted by Michael Wonder on 02 Jan 2023
Korea to exclude Australia from new drug pricing reference country list
30 December 2022 - HIRA has decided to leave Australia as a reference country when it sets drug prices next ...
Posted by Michael Wonder on 14 Dec 2022
HIRA sets up system to manage 'super-expensive' drugs
14 December 2022 - The Health Insurance Review and Assessment Service (HIRA) said it would operate a system to manage ...
Posted by Michael Wonder on 01 Dec 2022
Takeda Korea's Kynteles SC wins insurance benefit
1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by ...
Posted by Michael Wonder on 28 Nov 2022
'Reimbursement criteria for CGRP inhibiting migraine drugs not realistic'
28 November 2022 - The CGRP (calcitonin gene-related peptide) inhibitors, developed to prevent adult migraines, have recently been registered on ...
Posted by Michael Wonder on 27 Oct 2022
MSD's Zerbaxa becomes Korea's newest antibiotic to receive reimbursement
27 October 2022 - MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after ...
Posted by Michael Wonder on 12 Oct 2022
‘Current standard for stopping insurance benefits for SMA treatment harsh on adult patients’
12 October 2022 - Spinraza (nusinersen sodium), the first spinal muscular atrophy treatment that won the insurance coverage quickly since ...
Posted by Michael Wonder on 26 Sep 2022
Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails
22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the ...
Posted by Michael Wonder on 11 Sep 2022
Health movement in South Korea fights for universal access to medicines
10 September 2022 - Civil society in South Korea renewed its commitment to ensure universal access to medicines and public pharmaceutical ...
Posted by Michael Wonder on 01 Sep 2022
Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis
1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment ...
Posted by Michael Wonder on 11 Aug 2022
Amgen's acute lymphoblastic leukaemia drug Blincyto passes reimbursement review
11 August 2022 - Amgen's acute lymphoblastic leukaemia treatment Blincyto (blinatumomab) passed the reimbursement review about two years after expanding ...
Posted by Michael Wonder on 02 Aug 2022
Delay of Evrysdi reimbursement review denies SMA patients' right to drug choice
2 August 2022 - The Government has been dragging its feet to review insurance benefits for Roche's new spinal muscular ...
Posted by Michael Wonder on 02 Aug 2022
Korea's first gene treatment for SMA Zolgensma gets insurance benefits
2 August 2022 - Novartis Korea said Monday that it released Zolgensma, the nation's first gene replacement treatment for spinal ...